Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc. is focused on the use of cyclodextrins in drug development in treatment for Niemann-Pick disease Type C (NPC). The mission of Cyclo Therapeutics, Inc. is to develop, manufacture, and distribute cyclodextrin-based high value products. Their products treat disease, improve quality of life, and provide solutions in a broad range of applications including pharmaceutical formulation, medical diagnostics, cosmetics, nutraceuticals, and nutrition.

For more information, please visit cyclotherapeutics.com.

This page is dedicated to news and information about Cyclo Therapeutic’s therapies for use in Niemann-Pick disease Types C (NPC). Information is released as it becomes available.

Patient and Trial Information

Lise Kjems, Chief Medical Officer
lise.kjems@cyclodex.com

Lori Gorski, Patient Liaison
lori.gorski@cyclodex.com

Clinical Trial Information
Transport NPC
NPC Spotlight Spotlight on Niemann-Pick disease type C

Latest News

Update from Cyclo Therapeutics
Cyclo Therapeutics, Inc. is pleased to announce the last patient has been enrolled in the Company’s pivotal Phase 3 study (TransportNPC™) evaluating Trappsol® Cyclo™ for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type C1.

Read the message from Cyclo Therapeutics.
Read the complete announcement.

05/30/2024

Update from Cyclo Therapeutics
Cyclo Therapeutics announces positive outcome from type C meeting with the U.S. FDA discussing Trappsol® Cyclo™ Clinical Program for the treatment of Niemann-Pick Disease type C1. Read complete announcement.

12/18/2023

Update from Cyclo Therapeutics
Cyclo Therapeutics published positive data from their Phase 2 study of Trappsol Cyclo in the journal of Molecular Genetics and Metabolism Reports. Read the full press release which includes additional commentary from the principal investigator, Dr. Caroline Hastings.

06/29/2023

Update from Cyclo Therapeutics
Dr. Caroline Hastings, Global Principal Investigator and Head of the Global Steering Committee for the Phase 3 study TransportNPC™ shares an update on their progress to date to advance this pivotal study in patients with Niemann-Pick Type C1. Read the update.

06/09/2023

Update from Cyclo Therapeutics
We are continuing our Phase 3 study TransportNPC™ (Intravenous 2-hydroxypropyl-ß-cyclodextrin), to evaluate the safety and efficacy of a potential disease modifying therapy to treat NPC. This is the most extensive and advanced study underway in NPC and we are pleased to let you know that we are approximately 50% enrolled, and on track to complete enrollment by the end of this year. This is a large global study, and our sites in the United States are quite active, including:

UCSF Benioff Children’s Hospital Oakland
Cincinnati Children’s Hospital Medical Center
UPMC Children’s Hospital (Pittsburgh)
Lysosomal and Rare Disorders Research & Treatment Center (Fairfax, Virginia)

We understand that participating in a clinical trial is a big commitment, both for patients and their caregivers. We are pleased to share that within the United States, participants in this study will have the option of receiving their biweekly infusions at home. While some visits to your clinical trial site are still required, many of your infusions may be given at home. We hope giving patients and caregivers the option to remain at home will reduce travel and daily living disruptions and allow patients to receive the study infusion in the comfort of their home surrounded by loved ones.

We look forward to connecting with those of you attending the NNPDF annual meeting in Orlando. For any questions about Cyclo or TransportNPC™, contact lori.gorski@cyclodex.com.

05/30/2023

Cyclo Therapeutics’ May 2023 newsletter is live. Senior Medical Science Liaison, Joseph Mejia, MD shares an update on Phase 3 Study home infusion availability and get to know our very own Laurie Turner, NNPDF Family Services Manager. Read more.

05/01/2023

Cyclo Therapeutics’ January 2023 newsletter is live. Scott Fine, CEO shares an update on their ongoing Phase 3 study, TransportNPC™ and a recap of key activities delivered last year. Read more.

01/18/2023

Cyclo Therapeutics provides clinical program update and highlights recent achievements. Read complete update.

01/13/2023

Cyclo Therapeutics announces the publication of Phase 1 data for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease type C1. Read complete update.

10/19/2022

Cyclo Therapeutics announces the formation of a Global Steering Committee comprised of leading experts to advise on the global Phase 3 clinical development program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C. Read complete update.

02/03/2022

The following update has been shared with the NNPDF from Cyclo Therapeutics on their TransportNPC trial, which is currently enrolling. Read complete update.

12/21/2021

Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease. Read full press release.

12/10/2021

The following update has been shared with the NNPDF from Cyclo Therapeutics on their TransportNPC trial, which is currently enrolling. Read complete update.

10/12/2021

Cyclo Therapeutics announces their design of pivotal Phase 3 study evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1 patient enrollment is on track to commence in Q2 2021. For complete announcement click here.

04/27/2021

Cyclo Therapeutics announces their Phase III pivotal trial using Trappsol® Cyclo™ will be enrolling soon. For complete announcement click here.

04/14/2021

Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1). For complete announcement click here.

03/25/2021

Cyclo Therapeutics receives positive opinion from the Paediatric Committee of the European Medicines Agency on the agreement of a paediatric investigation plan for Trappsol® Cyclo™. For complete announcement click here.

03/09/2021

Cyclo Therapeutics, Inc. announces it’s last patient last visit in their Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick disease Type C. For complete announcement click here.

03/04/2021

Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021. For complete announcement click here.

02/09/2021

Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021. For complete announcement click here.

01/26/2021

Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick disease Type C. For complete announcement click here.

01/05/2021

Cyclo Therapeutics announces Two Presentations at WORLDSymposium2021.

CLICK HERE For complete announcement.

11/19/2020

Cyclo Therapeutics announces its Phase 3 pivotal program can begin enrollment of Trappsol® Cyclo™ for treatment of Niemann-Pick disease Type C.

CLICK HERE For complete announcement.

10/21/2020

Cyclo Therapeutics to Present at 2020 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom

CLICK HERE for complete announcement.

09/21/2020

Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick disease Type C1 (NPC1)

CLICK HERE for complete announcement.

09/08/2020

Cyclo Therapeutics Closes $2.8 Million Private Placement led by Novit LP with $1.0 Million

CLICK HERE for complete announcement.

08/27/2020

A Message from Cyclo Therapeutics to the NPC Community

CLICK HERE for complete announcement.